Gritstone Oncology Inc. (NASDAQ: GRTS) is -23.75% lower on its value in year-to-date trading and has touched a low of $5.42 and a high of $12.96 in the current 52-week trading range. The GRTS stock was last observed hovering at around $6.84 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $18.50 for the next 12 months. It is also 77.71% off the consensus price target high of $31.00 offered by 7 analysts, but current levels are 56.81% higher than the price target low of $16.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $6.91, the stock is 5.22% and 1.77% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.61 million and changing 1.02% at the moment leaves the stock -13.38% off its SMA200. GRTS registered -30.35% loss for a year compared to 6-month loss of -20.65%. The firm has a 50-day simple moving average (SMA 50) of $6.58 and a 200-day simple moving average (SMA200) of $7.74.
The stock witnessed a 5.07% gain in the last 1 month and extending the period to 3 months gives it a 9.62%, and is 3.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.95% over the week and 6.08% over the month.
Gritstone Oncology Inc. (GRTS) has around 176 employees, a market worth around $255.27M and $4.30M in sales. Distance from 52-week low is 27.49% and -46.68% from its 52-week high. The company has generated returns on investments over the last 12 months (-72.90%).
Gritstone Oncology Inc. (GRTS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Gritstone Oncology Inc. (GRTS) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 2 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Gritstone Oncology Inc. is expected to release its quarterly report on 08/17/2020 and quarterly earnings per share for the current quarter are estimated at -$0.73 with sales reaching $1.24M over the same period.The EPS is expected to shrink by -26.80% this year, but quarterly earnings will post 13.40% year-over-year. Quarterly sales are estimated to grow 7.80% in year-over-year returns.
Gritstone Oncology Inc. (GRTS) Top Institutional Holders
106 institutions hold shares in Gritstone Oncology Inc. (GRTS), with 3.75M shares held by insiders accounting for 10.07% while institutional investors hold 88.04% of the company’s shares. The shares outstanding are 36.80M, and float is at 33.36M with Short Float at 10.30%. Institutions hold 79.17% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 5.24 million shares valued at $30.51 million. The investor’s holdings represent 14.07% of the GRTS Shares outstanding. As of Mar 30, 2020, the second largest holder is Svennilson Peter with 3.1 million shares valued at $18.06 million to account for 8.33% of the shares outstanding. The other top investors are Versant Venture Management, LLC which holds 3.1 million shares representing 8.33% and valued at over $18.06 million, while Redmile Group, LLC holds 8.23% of the shares totaling 3.07 million with a market value of $17.86 million.
Gritstone Oncology Inc. (GRTS) Insider Activity
A total of 0 insider transactions have happened at Gritstone Oncology Inc. (GRTS) in the last six months, with sales accounting for 0 and purchases happening 0 times.